دورية أكاديمية
أعرض في EDS

Survivin silencing improved the cytotoxicity of carboplatin and melphalan in Y79 and primary retinoblastoma cells.

التفاصيل البيبلوغرافية
العنوان: Survivin silencing improved the cytotoxicity of carboplatin and melphalan in Y79 and primary retinoblastoma cells.
المؤلفون: Passos Gibson V; Gene Delivery Laboratory, Faculty of Pharmacy, Université de Montréal, H3C 3J7 Montréal, Québec, Canada., Derbali RM; Gene Delivery Laboratory, Faculty of Pharmacy, Université de Montréal, H3C 3J7 Montréal, Québec, Canada., Phan HT; Gene Delivery Laboratory, Faculty of Pharmacy, Université de Montréal, H3C 3J7 Montréal, Québec, Canada., Tahiri H; Department of Pediatrics, Physiology and Pharmacology, Université de Montréal, H3C 3J7 Montréal, Québec, Canada., Allen C; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON M5S 3M2, Canada., Hardy P; Department of Pediatrics, Physiology and Pharmacology, Université de Montréal, H3C 3J7 Montréal, Québec, Canada., Chain JL; Gene Delivery Laboratory, Faculty of Pharmacy, Université de Montréal, H3C 3J7 Montréal, Québec, Canada; Université de Bordeaux, ARNA Laboratory, INSERM U1212, CNRS UMR 5320, F-33016 Bordeaux, France. Electronic address: jeanne.leblond-chain@inserm.fr.
المصدر: International journal of pharmaceutics [Int J Pharm] 2020 Nov 15; Vol. 589, pp. 119824. Date of Electronic Publication: 2020 Aug 27.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier/North-Holland Biomedical Press Country of Publication: Netherlands NLM ID: 7804127 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-3476 (Electronic) Linking ISSN: 03785173 NLM ISO Abbreviation: Int J Pharm Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Amsterdam, Elsevier/North-Holland Biomedical Press.
مواضيع طبية MeSH: Retinal Neoplasms* , Retinoblastoma*/drug therapy , Retinoblastoma*/genetics, Apoptosis ; Carboplatin ; Cell Line, Tumor ; Humans ; Inhibitor of Apoptosis Proteins/genetics ; Melphalan ; RNA, Small Interfering ; Survivin/genetics
مستخلص: Survivin stands out as one of the most specific cancer targets discovered to date. Although single inhibition, e.g. through small interfering RNA (siRNA), has shown modest results in clinical trials, its combination with drugs holds promise to sensitize cancer cells to chemotherapeutics. In this study, we propose a sequential treatment of siRNA survivin followed by chemotherapy. Firstly, we demonstrated that siRNA-loaded switchable lipid nanoparticles (siLNP) silence survivin in a panel of cancer cell lines. Subsequently, we selected retinoblastoma (RB) as our model to screen four chemotherapeutic agents: carboplatin, topotecan, melphalan or teniposide. The effect of drugs on survivin expression and caspase-3 was investigated by RT-qPCR. The best drug combination was selected measuring the viability, survivin expression and the selectivity of the treatment. Our stepwise method revealed that siRNA delivery by switchable LNP sensitized Y79, but not the healthy APRE-19 cell line, to carboplatin and melphalan cytotoxicity. This ability was validated on primary human RB cells. Finally, the distinct behavior of the drugs demonstrated that a diligent screening of drugs should be envisioned when looking for synergy with survivin. Our sequential approach highlighted carboplatin and melphalan as agents to be investigated in future survivin-associated in vivo testing to tackle RB.
(Copyright © 2020 Elsevier B.V. All rights reserved.)
فهرسة مساهمة: Keywords: Cancer; Cationic switchable lipid; Retinoblastoma; Survivin targeting siRNA; Switchable lipid nanoparticles
المشرفين على المادة: 0 (Inhibitor of Apoptosis Proteins)
0 (RNA, Small Interfering)
0 (Survivin)
BG3F62OND5 (Carboplatin)
Q41OR9510P (Melphalan)
تواريخ الأحداث: Date Created: 20200831 Date Completed: 20210617 Latest Revision: 20210617
رمز التحديث: 20221213
DOI: 10.1016/j.ijpharm.2020.119824
PMID: 32861768
قاعدة البيانات: MEDLINE
الوصف
تدمد:1873-3476
DOI:10.1016/j.ijpharm.2020.119824